Related Experiment Video

Updated: Aug 29, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

[Epidermal growth factor receptor and chemoprevention of epithelial tumor: rationale and development methods]

Amine Masmoudi1, Jérome Fayette, Khemaies Slimane

  • 1Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif.

Bulletin Du Cancer
|February 7, 2004
PubMed

Insights

Targeting the REGF pathway offers promising chemopreventive and anticancer effects by regulating cell growth and apoptosis. This review explores research on chemopreventive strategies focused on REGF signaling in epithelial tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Chemoprevention

Background:

  • The REGF pathway is frequently dysregulated in carcinogenesis.
  • REGF signaling promotes uncontrolled cell proliferation, apoptosis resistance, angiogenesis, and invasion.
  • Overexpression of REGF is common in many epithelial tumors.

Purpose of the Study:

  • To review the rationale for targeting the REGF pathway in cancer chemoprevention.
  • To highlight ongoing research in chemopreventive approaches targeting REGF.
  • To discuss the cellular mechanisms of REGF in cancer development.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of research on REGF pathway dysregulation in cancer.
  • Synthesis of data on chemopreventive strategies targeting REGF.

Main Results:

  • REGF pathway dysregulation is a key event in many epithelial cancers.
  • Targeting REGF offers potential for chemoprevention and cancer treatment.
  • Understanding REGF's role in proliferation and apoptosis is crucial.

Conclusions:

  • The REGF pathway represents a significant target for cancer chemoprevention.
  • Further research into REGF-targeted therapies is warranted.
  • Modulating REGF signaling may reverse or suppress carcinogenic processes.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...